CAAS Capital Management’s RxSight RXST Stock Holding History

CAAS Capital Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100,000	Closed	-$1.27M	–	1018
2021 Q3	$1.27M	Buy	+100,000	New	+$1.38M	0.03%	438

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's RXST Position: Q4 2021 in Review

CAAS Capital Management sold out of RxSight (RXST) in Q4 2021, closing a stake of 100,000 shares — an estimated $1.27M sold.

CAAS Capital Management first reported a position in RXST in Q3 2021 and held it in 1 quarter. The position peaked at $1.27M in Q3 2021. 40 funds tracked by Wall St. Rank hold RXST as of Q4 2021.

CAAS Capital Management reported no remaining RxSight position as of Q4 2021 after selling out during the quarter.
CAAS Capital Management sold 100,000 RxSight shares in Q4 2021, an estimated $1.27M.
CAAS Capital Management first reported a position in RxSight in Q3 2021 and held it in 1 quarter.
CAAS Capital Management's RxSight position peaked at $1.27M in Q3 2021.
40 funds tracked by Wall St. Rank held RxSight as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.